A practical reference on dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
== Clinical significance == Anti-endomysial antibodies (EMA) are present in celiac disease. They do not cause any direct symptoms to muscles, but detection of EMA is useful in the diagnosis of the disease.
=== Legal status === The FDA issued the approval of escitalopram for major depression in August 2002, and for generalized anxiety disorder in December 2003. In May 2006, the FDA approved a generic version of escitalopram by Teva. In July 2006, the U.S. District Court of Delaware decided in favor of Lundbeck regarding a patent infringement dispute and ruled the patent on escitalopram valid. In 2006, Forest Laboratories was granted an 828-day (2 years and 3 months) extension on its US patent for escitalopram. This pushed the patent expiration date from 7 December 2009, to 14 September 2011. Together with the 6-month pediatric exclusivity, the final expiration date was 14 March 2012.
Also, while the United States is one of the countries critical to Philippine drug war campaign, most of the militant groups – particularly left-wing groups – also criticize Philippine-US relations due to the United States' "imperialism" and neoliberal policies.
Sources: en.wikipedia.org
1st Special Air Service 2nd Special Air Service 3rd Special Air Service – 3e Régiment de Chasseurs Parachutistes 4th Special Air Service – 2e Régiment de Chasseurs Parachutistes 5th Special Air Service – lineage continued by Belgian Special Forces Group F Squadron – responsible for signals and communications It was tasked with parachute operations behind the German lines in France and carried out operations supporting the Allied advance through France (Operations Houndsworth, Bulbasket, Loyton, Kipling and Wallace-Hardy), Belgium, the Netherlands (Operation Pegasus), and eventually into Germany (Operation Archway and Operation Howard). As a result of Hitler's issuing of the Commando Order on 18 October 1942, the members of the unit faced the additional danger that they would be summarily executed if captured by the Germans. In July 1944, following Operation Bulbasket, 34 captured SAS commandos were indeed summarily executed by the Germans; in October 1944, in the aftermath of Operation Loyton, another 31 captured SAS commandos were summarily executed by the Germans. The last original member of the Special Air Service and the last survivor of the Long Range Desert Group, Mike Sadler, died on 4 January 2024, at the age of 103.
All the alkali metals are highly reactive and are never found in elemental forms in nature. Because of this, they are usually stored in mineral oil or kerosene (paraffin oil). They react aggressively with the halogens to form the alkali metal halides, which are white ionic crystalline compounds that are all soluble in water except lithium fluoride (LiF). The alkali metals also react with water to form strongly alkaline hydroxides and thus should be handled with great care. The heavier alkali metals react more vigorously than the lighter ones; for example, when dropped into water, caesium produces a larger explosion than potassium if the same number of moles of each metal is used. The alkali metals have the lowest first ionisation energies in their respective periods of the periodic table because of their low effective nuclear charge and the ability to attain a noble gas configuration by losing just one electron. Not only do the alkali metals react with water, but also with proton donors like alcohols and phenols, gaseous ammonia, and alkynes, the last demonstrating the phenomenal degree of their reactivity. Their great power as reducing agents makes them very useful in liberating other metals from their oxides or halides. The second ionisation energy of all of the alkali metals is very high as it is in a full shell that is also closer to the nucleus; thus, they almost always lose a single electron, forming cations.
Blanche absinthe ("white" in French, also referred to as la Bleue in Switzerland) is bottled directly following distillation and reduction and is uncoloured (clear). Blanches tend to have a clean, smooth flavour with strongly individuated tasting notes. The name la Bleue was originally a term used for Swiss bootleg absinthe, which was bottled colourless so as to be visually indistinct from other spirits during the era of absinthe prohibition, but has become a popular term for post-ban Swiss-style absinthe in general. Blanches are often lower in alcohol content than vertes, though this is not necessarily so; the only truly differentiating factor is that blanches are not put through a secondary maceration stage, and thus remain colourless like other distilled liquors. Verte absinthe ("green" in French, sometimes called la fée verte) begins as a blanche and is altered by a secondary maceration stage, in which a separate mixture of herbs is steeped into the clear distillate before bottling. This confers an intense, complex flavor as well as a peridot green hue. Vertes represent the prevailing type of absinthe that was found in the 19th century. Vertes are typically more alcoholic than blanches, as the high amounts of botanical oils conferred during the secondary maceration only remain miscible at lower concentrations of water, thus vertes are usually bottled at closer to still strength. Artificially colored green absinthes may also be claimed to be verte, though they lack the characteristic herbal flavors that result from maceration in whole herbs.
City Hall of Valencina - Official site of the City Hall of Valencina de la Concepción Valencina de la Concepción - Sistema de Información Multiterritorial de Andalucía - 2011 archive Valencina: A copper age polity (2025) Urbanismo en Valencina - Information about town planning in Valencina de la Concepción Dolmen of Matarrubilla - Information about the dolmen of Matarrubilla - 2022 archive Dolmen of La Pastora - Information about the dolmen of La Pastora - 2022 archive Studies in Iberian Archaeoastronomy: (8) Orientations of Megalithic and Tholos Tombs of Portugal and Southwest Spain
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.